Sales & Marketing News | pharmaphorum

News

Lykos CEO steps down after MDMA is rejected by FDA

The fallout from the FDA's recent decision not to approve Lykos Therapeutics' psychedelic treatment has spread to its senior management, with chief executive Amy Emerson stepping down.

News

AstraZeneca China HQ: at Shanghai Zhangjiang Hi-Tech Park

China detains AstraZeneca workers in data, imports probe

AstraZeneca has confirmed that some of its current and former employees have been taken into custody in China as part of an investigation into data privacy breaches and the import of unlice

News

J&J sweetens controversial talc settlement deal

In a bid to put litigation over the safety of its talc products into the rearview mirror, Johnson & Johnson has added another $1.1 billion to its settlement offer, according to media re

News

Advanz wins stay on EU revocation of Ocaliva license

There's been another twist to the tale of Advanz Pharma's efforts to keep its primary biliary cholangitis (PBC) therapy Ocaliva on the market in the EU.

News

Illumina avoids hefty EU fine over Grail merger

The top court in the EU has ruled that the European Commission exceeded its authority in its investigation of the $8 billion merger between Illumina and Grail, albeit too late to halt the f

News

Advanz Pharma's bid to keep Ocaliva on EU market fails

The European Commission has followed the advice of its human medicines committee and revoked the conditional marketing authorisation for Advanz Pharma's Ocaliva therapy for primary biliary

Lykos CEO steps down after MDMA is rejected by FDA

China detains AstraZeneca workers in data, imports probe

J&J sweetens controversial talc settlement deal

Advanz wins stay on EU revocation of Ocaliva license

Illumina avoids hefty EU fine over Grail merger

Advanz Pharma's bid to keep Ocaliva on EU market fails

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

News

Editor's Picks